Quick Answer
PUMA BIOTECHNOLOGY, INC. reported Total Revenue of $228.37 million for the year ending 2025.
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -0.9% in Total Revenue from 2024 to 2025.
- This data is from PUMA BIOTECHNOLOGY, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $6.08 million | Q3 2017: $6.08 million | Q4 2017: $21.61 million | Q4 2017: $21.61 million | Q1 2018: $66.52 million | Q1 2018: $66.52 million | Q2 2018: $50.77 million | Q3 2018: $62.63 million | Q4 2018: $71.08 million | Q1 2019: $99.07 million | Q2 2019: $53.92 million | Q3 2019: $56.35 million | Q4 2019: $62.92 million | Q1 2020: $51.22 million | Q2 2020: $70.58 million | Q3 2020: $50.75 million | Q4 2020: $52.56 million | Q1 2021: $98.17 million | Q2 2021: $53.38 million | Q3 2021: $46.25 million | Q1 2022: $45.74 million | Q2 2022: $59.52 million | Q3 2022: $57.10 million | Q1 2023: $52.78 million | Q2 2023: $54.57 million | Q3 2023: $56.12 million | Q1 2024: $43.77 million | Q2 2024: $47.08 million | Q3 2024: $80.54 million | Q1 2025: $46.01 million | Q2 2025: $52.44 million | Q3 2025: $54.48 million.
- Over the full 10 years of available data (2017 to 2025), PUMA BIOTECHNOLOGY, INC.'s Total Revenue has grown by 724.9%.
- Historical annual values: Fiscal year 2025: $228.37 million | Fiscal year 2024: $230.47 million | Fiscal year 2023: $235.64 million | Fiscal year 2022: $228.03 million | Fiscal year 2021: $253.16 million | Fiscal year 2020: $225.11 million | Fiscal year 2019: $272.26 million | Fiscal year 2018: $250.99 million | Fiscal year 2017: $27.69 million | Fiscal year 2017: $27.69 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: